A Single-arm, Multicenter, Phase III Study to Assess Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients of 2 to <18 Years of Age With Primary Immunoglobulin A Nephropathy (IgAN)
Latest Information Update: 04 Jun 2025
At a glance
- Drugs Iptacopan (Primary)
- Indications IgA nephropathy
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 04 Jun 2025 New trial record